A*0201 or HLA-B*3501 haplotypes indicate that activated HIV-1-specific CD8 ϩ effector cells that recognize 1 or 2 immunodominant epitopes decline with aggressive antiretroviral treatment [3, 15] . It remains unclear whether this extends to the remaining patient population and whether the memory CTL pool also decreases concurrently with declines in activated antigen-specific effectors. Since major histocompatibility complex (MHC) peptide tetramer-binding cells represent only part of the potential CTL repertoire, the breadth of antigen-specific CD8 ϩ T cell counts may be less well appreciated by this modality. It is also conceivable that, with improved T cell help, CD8
ϩ T effector cells may emerge that recognize new previously unidentified epitopes. To address these issues, we prospectively examined the T cell phenotype and cytolytic responses in 41 patients with chronic HIV-1 infection who received zidovudine, lamivudine, and indinavir over 16-24 weeks.
Patients and Methods

Study Population
Forty-one HIV-1-infected study participants were recruited at the AIDS Clinical Trials Group (ACTG) units of 2 institutions, the University of Washington and Harvard University. Volunteers consented for enrollment in both the parent study, ACTG 343 [9] , and the immunology substudy 879 described here. Eligibility criteria included peripheral blood CD4 ϩ T cell counts 1200 cells/mm 3 , plasma HIV-1 RNA level у1000 copies/mL, and no previous use of lamivudine and protease inhibitors. The immunologic studies were done during the 24-week induction period, when all patients received open-label zidovudine (Retrovir, 300 mg twice daily; Glaxo Wellcome), lamivudine (Epivir, 150 mg twice daily; Glaxo Wellcome), and indinavir (Crixivan, 800 mg every 8 h; Merck). Anticoagulated blood was obtained at weeks 1 and 2 before therapy and at weeks 4, 8, 16 , and 24 during therapy.
Virus Load Measurements
Plasma HIV-1 RNA levels were measured by Amplicor HIV assay (Roche Molecular Systems) at the Johns Hopkins Medical Laboratory (Baltimore).
Phenotypic T Cell Analysis
Three-color flow cytometric analysis was performed on fresh whole blood, to examine T cell phenotypic changes over [16] [17] [18] [19] [20] [21] [22] [23] [24] weeks. The percentages of CD4 ϩ and CD8 ϩ T cell counts expressing various activation and memory or naive cell surface proteins were determined by staining with mixtures of 3 antibodies including either Cy-Chrome-conjugated anti-CD4 or anti-CD8 and the antibody pairs fluorescein isothiocyanate (FITC)-anti-CD45RA/phycoerythrin (PE)-anti-CD62L, FITC-anti-CD28/PE-anti-CD95, or FITC-anti-HLA-DR/PE-anti-CD38. All antibodies were obtained from PharMingen. In total, 20 mL of each FITC and PE antibody combination and 20 mL of a Cy-Chrome-conjugated antibody were added to 100 mL of whole blood, and these were incubated for 30 min at 4ЊC. The cells then were washed twice with PBS containing 0.1% sodium azide and resuspended in 400 mL of 1% paraformaldehyde in PBS. We analyzed cells with a Coulter Epics-XL flow cytometer with a 488-nm argon laser for excitation. In all, 5000 events were used for analysis. Color compensation was done by using peripheral blood stained separately with anti-CD8 antibodies conjugated with FITC, PE, and Cy-Chrome. Percentages of CD4 ϩ or CD8 ϩ cell counts expressing various activation and memory antigens were determined by gating on the Cy-Chrome-positive cells. We then determined the percentages of these cells that stained with FITC and/or PE. Thus, non-T cells were excluded from the 3-color analysis by gating on lymphocytes on the basis of light scatter and the expression of either CD4 or CD8.
Tetramer Staining of CD8
+ T Cells
Tetramer-binding studies were performed on HLA-A2-positive patients from the 2 clinical sites. About to periph- 6 6 1 ϫ 10 2 ϫ 10 eral blood mononuclear cells (PBMC) frozen before and at different times after the initiation of antiretroviral treatment were thawed, washed, and immediately stained with either the PE-conjugated HLA-A2-gag (SLYNTVATL) or the HLA-A2-pol (ILKEPVHGV) tetramer. In brief, PBMC were washed with PBS containing 2% fetal calf serum (FCS), were resuspended in 100 mL of PBS, and were incubated with the appropriate tetramer for 15 min at room temperature. A cocktail of antibodies specific for CD8ab, CD3, and CD8a was added for another 15 min. The cells then were washed and resuspended in 0.5 mL of 1% formalin-PBS. The monoclonal antibodies (MAbs) used were directly coupled to FITC, PE-Texas red (ECD), or allophycocyanin (APC). The following MAbs were used: anti-CD8a (Leu2a)-FITC (Becton Dickinson), anti-CD8ab (2ST8-5H7)-ECD (Beckman-Coulter), and APC-conjugated anti-CD3 (Beckman-Coulter). PE-coupled tetrameric HLA class I-Gag or Pol complexes, anti-CD8ab-ECD, anti-CD3-APC, and anti-CD8a-FITC were used for 4-color flow cytometric analyses. Since the tetramer-binding cells express CD8ab molecules, all analyses were performed by gating on CD8ab ϩ CD3 ϩ cells, and a total of 20,000 gated cells were analyzed. Data were analyzed with several software products (WinMDI, version 2.7, Joseph Trotter; Microsoft PowerPoint 97). Samples were analyzed on a dual laser FACSCalibur (Becton Dickinson) flow cytometer.
Quantitation of HIV-1-Specific Cytotoxicity by Limiting Dilution Assay (LDA)
HIV-1-specific cytotoxicity that recognizes either HIV-1 gene products or immunodominant epitopes was measured in patients with sufficient viable cryopreserved cells over the 16-week study period.
Recognition of HIV-1 gene products. Precursor CTL (pCTL) frequencies were determined by LDA after a 14-day stimulation, with modifications to methodology, as described elsewhere [2] . Assays were conducted in batch analysis on cryopreserved PBMC from individual donors obtained at the 5 time points. Serial dilutions (from 20,000 to 625 cells/well) of cryopreserved PBMC were plated in 96-well round-bottomed plates in 24-well replicates. Fresh autologous PBMC (3000 cells/well) infected with recombinant vaccinia virus (rVV)-encoding portions of HIV-1 env, gag, and pol genes (encoding protease only; vP1291) at an MOI of 5 (provided by J. Tartaglia, Virogenetics) and gamma irradiated (3000 rad) were used as HIV-specific stimulator cells. Irradiated allogeneic PBMC (50,000 cells), feeder cells, and 50 U/mL of human recombinant interleukin-2 (Chiron) were added to each well.
On day 14, the 51
Cr release assay was done as described elsewhere [2] . Radiolabeled autologous Epstein-Barr virus-transformed B lymphoblastoid cell lines (B-LCLs), previously infected with rVV (MOI, 1.5), containing either HIV-1 MN env (vP1174), HIV-1 LAI gag (vP1287), HIV-1 LAI pol (vP1288), or the control WR vaccinia (Lvar; Virogenetics) served as target cells. These were plated at 5000 cells/well, in addition to unlabeled "cold" B-LCL targets infected with L-var (ratio of cold-to-hot targets, 20:1); the latter was added to better discriminate HIV-specific from vaccinia-specific cytolysis. The percentage of lysis was calculated from the mean of triplicate measurements, and wells with lysis exceeding the mean spontaneous release by 3 SD were considered to be positive. The precursor frequencies were calculated, as described elsewhere [16] , and were expressed as pCTL/10 6 PBMC.
Recognition of HIV-1-specific immunodominant epitopes.
PBMC of 11 patients with HLA class I haplotypes in whom HIV-1 CTL epitopes have been defined (Los Alamos database) were evaluated for cytolysis of autologous targets pulsed with selected 8-or 9-aa peptide epitopes in LDAs. We used the following HIV-1 peptides and their restricting MHC class I molecules in these assays: Gag p17 SLYNTVATL (HLA-A2), Pol ILKEPVHGV (HLA-2), Gag p17 GGKKKYKL (HLA-B8), Pol GPKVKQWPL (HLA-B8), p17 KIRLRPGGK (HLA-A3), and p17 NSSKVSQNY (HLA-B35). PBMC from each patient were assessed for the recognition of 2 peptides. The well-characterized ovalbumin CTL epitope peptide (SIINFEKL) [17] was used as a control. Assays were done, as described elsewhere [18] . In brief, cryopreserved PBMC were thawed and were serially diluted (from 16,000 to 125 cells/ 
NOTE. Wilcoxon signed rank tests. ϩ, Increases in cell counts or percentages; Ϫ, decreases in cell counts or percentages.
well) in 24 replicates in 96-well round-bottom microtiter plates. In all, autologous PBMC were incubated with 50 mg/mL of 6 2 ϫ 10 peptide solution in a shaking 37ЊC water bath for 2-3 h, were irradiated (3000 rad), and were added to the plates as stimulator cells ( cells/well). The cultures were maintained in 100 mL 4 2 ϫ 10 of medium containing 10% FCS supplemented with 10 U/mL of exogenous T cell growth factor (Lymphocult T; Biotest). Microcultures were fed at 5 and 10 days by the addition of 50 mL of medium containing Lymphocult T (10 U/mL). After 14 days in culture, the effector cells were assessed for cytotoxicity against 51 Crlabeled peptide-pulsed autologous B-LCL targets. Positive lysis was defined as 13 SD above the mean of the nonspecific cytotoxicity of all cultures. Precursor frequencies were calculated and were expressed as pCTL per 10 6 PBMC. Statistical analyses. We made paired comparisons of changes in T cell phenotypes from baseline to week 24 by using Wilcoxon signed rank tests. Baseline values were the mean of 2 pretreatment measurements taken within 2 weeks of each other, with the second taken on the day treatment began. Medians and quartiles were used to summarize T cell phenotypic markers and log 10 -transformed HIV-1-specific CTL responses. We used mixed-effects models to determine quantitative changes in memory CTL pools, since these are the standard method for analyzing longitudinal data by taking into account correlations within persons. Linear mixed-effects models were used separately for each HIV-1-specific Env and Gag/Pol-CTL response. Because the epitope-specific CTL responses had many nonresponders, we used conditional logistic regression for analysis.
Results
Treatment Effects on Virus Load
Before therapy, the 41 study participants exhibited a wide range of plasma viremia-from undetectable (!200 copies/mL) in 1 patient to 97,760 copies/mL (median, 15,920 copies/mL; table 1). Within 4 weeks of initiation of triple-drug therapy, most patients (22 [55%] of 41) suppressed plasma HIV-1 RNA to levels below the limits of assay detection (!200 copies/mL; table 1). Over the subsequent study period (weeks 8-24), these 22 subjects maintained suppression, and an additional 13 patients developed viral suppression (data for some later time points were not available for 5 patients). Incomplete suppression of viremia was observed in only 1 patient. Thus, tripledrug treatment lowered plasma viremia in 190% of patients during study months 4-6.
Changes in T Cell Phenotypes
To examine T cell phenotypic changes from baseline to week 24 in association with suppression of plasma viremia, we used Wilcoxon signed rank tests. Findings are summarized in table 2, and mean values are shown in figure 1 . The median CD4 ϩ T cell counts increased significantly to 163 cells/mL ( ; table 2); P ! .001 a similar increase was also noted by comparing mean counts (table 1) and median percentages (5.5%;
). When we P ! .001 stratified CD4
ϩ cell counts by expression of CD62L and the CD45RA isoform over the 24 weeks of treatment, the predominant increase was in the naive (CD45RA
ϩ cell population (table 2 and figure 1A ). There was a significant median increase in cell number (86 cells/mL, ) and percent-P ! .001 age (5%;
). Small but significant increases also were P ! .001 noted in CD4 ϩ T cells that expressed a memory phenotype figure 1C and 1D ). These changes may be associated with diminished viral replication, T cell activation, and apoptosis. In addition, there was an eventual increase in T cells expressing CD28, which was more striking in the CD4 ϩ subset (146 cells/mL; ; figure 1C ). P ! .001
Detection of HIV-1-Specific CD8 + T Cells by Tetramer Staining
To further examine the dynamics of the HIV-specific CD8 ϩ T cells with therapy, the presence of MHC-restricted class I epitopespecific CD8 ϩ T cells was examined by using MHC-peptide tetramer staining of cryopreserved PBMC in 10 HLA-A*0201-positive patients. Six of the 10 patients had detectable CD8 ϩ T cells binding to well-defined immunodominant epitopes within HIV-1 Gag (4 patients) and Pol (3 patients) before treatment ( 
16,
). Pol-specific tetramer-binding cells also de-0.75% ‫ע‬ 0.87% creased but to a lesser extent by week 16 (week 0, 0.24% ‫ע‬ , vs. week 16, ). Figure 2 shows findings in 0.07% 0.17% ‫ע‬ 0.06% 1 patient whose CD8 ϩ T cells recognized both the Gag and Pol epitopes and in whom a gradual decline in tetramer-binding cells occurred. In this case, Gag tetramer-binding cells decreased from 1.2% before drug therapy to 0.3% at week 16 after initiation of treatment; similarly, Pol tetramer-binding CD8 ϩ T cell counts decreased from 0.3% before to 0.1% at week 16 after start of therapy. Overall, the percentage of tetramer-binding CD8 ϩ T cell counts did not correlate with the pCTL frequency in the 7 patients, in whom both analyses were performed using the same Gag and Pol epitopes (data not shown).
HIV-1 Cytotoxic T Cell Responses
Recognition of HIV-1 gene products. To determine whether suppression of viremia leads to alterations in the memory CTL pool, we measured HIV-1-specific precursor CTL frequencies to HIV-1 Env and Gag/Protease gene products in a batch-limiting dilution analysis with cryopreserved PBMC, by comparing 2 pretreatment with 3 posttreatment time points in 23 patients. The 2 baseline Env and Gag/Protease CTL frequencies (median, 12.8 and 15.1/10 6 PBMC, respectively), measured 1 and 2 weeks before therapy, were similar ( and , respectively; figure P p .49 P p .72 3). Individual variation was exhibited over the treatment interval. Of note, the 2 patients with the greatest levels of fluctuation in pCTL frequencies also experienced breakthrough viremia (data not shown). Overall, HIV-1 Env and Gag/Protease cytotoxicities were remarkably constant when assessed over the 16-week period ( figure 3) . The Env-specific frequencies did not differ significantly between median baseline measurements (12.8/10
6 PBMC) and those at 4 weeks (13.0/10 6 PBMC; ) and at 16 weeks P p .27 (13.8/10 6 PBMC; ; figure 3 ). Likewise, the median Gag/ P p .19 Protease pCTL frequency was not significantly different between baseline and weeks 4 and 16 (15.7, 15.4, and 17.3/10 6 PBMC, respectively). Thus, quantitative changes in memory CTL pools that recognize HIV-1 structural gene products remain constant, despite marked reduction in plasma viremia.
Recognition of immunodominant epitopes.
To determine changes in memory CTL recognition of defined class I immunodominant epitopes, pCTL frequencies in 11 patients with sustained undetectable plasma viremia were analyzed to 2 immunodominant epitopes within the gag and pol genes restricted by 1 or 2 HLA class I haplotypes. Figure 4 shows representative findings in 4 patients. Of note, in 3 (27%) of the 11 patients, there was no recognition of the 2 immunodominant epitopes during the 16-week study. Only 4 (36%) of the 11 had detectable responses to у1 immunodominant epitope before combination antiretroviral therapy. Among these 4 cases, transient ( ) or n p 1 sustained ( ) increases in pCTL frequencies were demonn p 3 strated after treatment ( figure 4A-4C) . Moreover, in association with reductions in plasma viremia, new CTL recognition of 1 or 2 of the immunodominant epitopes emerged in 6 patients (54%; figure 4A, 4C, and 4D) . Thus, despite the decrease in activated CD8 ϩ T cells from which the in vivo HIV-1-specific effector cells are presumably derived, the overall memory CTL pool remained stable, with evidence of newly recognized epitopes or increased responses to previously recognized epitopes.
Discussion
Most patients with chronic HIV-1 infection require prolonged antiretroviral treatment to avoid further immunodeficiency and need a stronger immune defense to protect against HIV-1 disease. As best shown in simian immunodeficiency virus infection [19, 20] , as well as in HIV-1 infection [21] , class I MHC-restricted CD8 ϩ T cells play a central role in controlling infection. To maintain suppression of viral replication, the host must possess a memory pool of HIV-specific CD8 ϩ T cells, and CD4 ϩ T cell help may be required to sustain these activities. In this study, we 
dissected alterations in CD8
ϩ HIV-specific cells during the induction period of viral suppression with combination antiretroviral therapy. Our results demonstrate that the overall precursor CD8
ϩ CTL pool, which may include both immediate precursors of already differentiated effector cells and central memory cells [22] , remains stable during the induction period of viral suppression, despite a decline in activated effectors. In addition, new or additional CTL epitopes are commonly recognized, which is consistent with other reports of a few patients who developed either broadening or new epitope recognition after viral suppression [23, 24] .
These findings provide both complementary and additional insight to previous studies that examined alterations in tetramerbinding CD8 ϩ T cells [3, 15] . Of note, in this study, we determined responses in a relatively large number of patients with chronic HIV infection who had fairly well-preserved CD4 ϩ T cell counts (1200 copies/mL), unlike previous reports with fewer patients or with patients with acute HIV-1 infection. The decrease in activated (CD38 ϩ HLA-DR ϩ and CD95 ϩ ) CD8 ϩ T cells observed during the period of viral suppression is consistent with previous studies that examined phenotypic changes after treatment with protease inhibitors alone [25] or in combination [26] and in association with declines in MHC-peptide tetramer-binding CD8 ϩ
CD38
ϩ cells [27] . These results provide additional support to the assertion that terminally differentiated activated CD8
ϩ CTLs, so profoundly induced in HIV-1 infection, become less abundant as viral replication is suppressed with antiretroviral therapy.
Of equal importance and perhaps less often emphasized is the kinetics of the memory CTL pool during treatment, since the progeny of this population will provide long-term immune de- fense. We used the more standard LDA, which requires in vitro stimulation and expansion of antigen-specific CD8 ϩ T cells, because it remains the best quantitative method to assess the memory pool. This method provides an assessment of reactivities to both single epitopes and multiple gene products but may underestimate the frequency of HIV-1-specific responses if in vitro T cell proliferative capabilities are impaired. Our findings indicate that the overall memory CTL population remains stable during this period of rapid decline in viremia and activated CD8 ϩ T cells. The stability of the memory CD8 ϩ CTL pool was not reflected in sustained percentages and numbers of CD8 ϩ T cells expressing low-to-absent levels of CD62L and CD45RA during the first 24 weeks of therapy. It is possible that some HIV-specific CD8 ϩ T cells reverted to the CD45RA phenotype and that additional markers are needed to better discern the memory pool. Nonetheless, these findings denote stability in antigen specificity spanning the epitopes within HIV-1 structural gene products and indicate that the overall breadth of pCTL responses are maintained during this induction period of viral suppression.
These studies also emphasize that about one-third of patients did not recognize known immunodominant epitopes by either pCTL or tetramer-binding assays. Of 11 patients, 8 (73%) had CTL responses that recognized у1 immunodominant epitope restricted by common, but diverse, MHC class I molecules, and these responses remained stable throughout the 16-week study. In contrast, CD8 ϩ T cells from 6 of 10 HLA-A2-positive patients exhibited binding to 1 or 2 MHC-peptide tetramers, but these levels did not unexpectedly decrease over the course of treatment. It is reasonable to assume that the reduced antigen load associated with suppression of plasma viremia contributes to the lowering of activated CTL effector population detected by tetramer binding. However, additional studies that can distinguish between activated, terminally differentiated effectors from the memory pool, both of which should bind the MHC peptide tetramers, will be helpful in further dissecting the dynamics of the antigen-specific pool. Moreover, additional tetramers with peptides representing potential new epitope specificities will be useful.
It is important to contrast our findings with those recently reported [28] for 2 patients over nearly 2 years, in whom viral suppression was achieved but with substantial fluctuation. Ka-lams et al. [28] found an initial increase followed by a decrease in HIV-specific pCTL frequencies. Our study involved a larger patient population but a shorter time interval during which viral suppression was maintained. Considering the breadth of responses seen with more patients, we observed sustained pCTL frequencies. Clearly, common individual variation warrants examination of more patients to understand these trends. However, with the examination of distinct antigenic specificities, both new and increased responses are more commonly observed. This is consistent with the findings by Kalams et al. [28] and may represent redistribution of previously noncirculating effectors.
This investigation provides new information concerning the kinetics of CD8 ϩ effector and memory responses during the induction period of viral suppression. Our findings suggest that, even if the memory CD8 ϩ CTL pool is sustained, this immune defense alone will not be adequate to control HIV-1 infection once 1 or 2 of the antiretroviral agents are subsequently stopped. However, future studies may delineate chronically infected patients in whom therapy cessation is more feasible, on the basis of a sustained memory CTL pool, in addition to new epitope recognition, perhaps in conjunction with improved T cell help in chronically infected patients.
